Spectrum Pharma (SPPI) Tops Q3 EPS by 19c

Spectrum Pharma (NASDAQ: SPPI) reported Q3 EPS of ($0.22), $0.19 better than the analyst estimate of ($0.41).

“Spectrum has an expanding pipeline, significant near-term milestones, solid capitalization and a highly focused team,” said Joe Turgeon, President and CEO, Spectrum Pharmaceuticals. “In December, we look forward to results from Cohort 1 of our ZENITH20 study investigating poziotinib in lung cancer patients with hard-to-treat mutations. We recently submitted our BLA for ROLONTIS to the FDA, a key milestone, as we continue to execute on our strategic priorities.”

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Evogene chairman to address dissident shareholders on results call